• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    (2-Haloergolinyl)-N', N'-diethylurea derivatives of Formula I and the salts thereof, wherein R is hydrogen, alkyl of up to 6 carbon atoms, or alkenyl of up to 3 carbon atoms, X is halogen, is a CC single or CC double bond, and the urea residue in the 8-position can be in the a- or β-configuration, have neuro- psychotropic and antihypertensive properties. As a result, they are excellently suitable for inhibition of lactation, and for treatment of Parkinsonism. psychotic disturbances, and high blood pressure.
    公开号:SU1097199A3
    申请号:SU813366005
    申请日:1981-12-22
    公开日:1984-06-07
    发明作者:Хильшер Жан-Клод；Кер Вольфганг；Зауэр Герхард；Шнайдер Херберт；Вахтель Хельмут
    申请人:Шеринг Аг (Фирма)；
    IPC主号:
    专利说明:

    3.79 g of 1,1-diethyl-3- (2-brbm 9,10-didehydro-6-methyl-8r-ergolinyl) urea are obtained in the form of a hydrobromic acid salt. M.p. 189-193 ° C, (o-li, 144.4 ° (in methanol). UV: E22J 23200; e-2300; Bzoo 10900 .. Example 4. A) 5.35 g of lysergic acid methyl ester IO dissolve in 72 ml of tetrahydrofuran and 8 ml of hexamethylphosphoric triamide To this mixture, 10.70 g of phenyltrimethylammonium perbromide in 267 ml of tetrahydrofuran is added dropwise to the mixture at room temperature with nitrogen. After stirring for 2 hours at room temperature, it is filtered off under vacuum, the residue is washed with 8Q ml of tetrahydrofuran and recrystallized from methanol in the presence of activated carbon. 4.50 g of methyl 2-bromo-meroxy acid ester are obtained in the form of hydrobromide. M.p. 124-125 b) 4.24 g of 2-bromo-mericine methyl ester hydrobromide is dissolved in 254 ml of chloroform and stirred with 106 ml of anhydrous gi: 1 Razine for 17 h at 50 ° C while passing nitrogen. The mixture is then cooled to room temperature and shaken with 500 ml of saturated sodium chloride solution. The phases are separated. The aqueous phase is extracted three times with chloroform. The combined chloroform extracts are washed twice with water and dried over sodium sulfate. After evaporation under pressure and crystallization from 25 ml of methanol, 2.35 g of isomeric 2-bromo- (meo) -lysergic hydrazide is obtained. M.p. 218 ° C (with decomposition), (sz1) d 343.2 ° (in pyridine). c) 1.0 g of the isomeric 2-bromo- (iso) -legic acid hydrazide is dissolved in 18 ml of 0.2 N hydrochloric acid and treated with ice cooling 3.5 ml of 1N. sodium nitrite solution and 21.5 ml 0.2 n. hydrochloric acid. After about 5 minutes, the mixture was separated by 170 ml of toluene and 28.5 ml of 1H. ammonium hydroxide solution, the phases are separated, the aqueous phase is extracted again with toluene and dried over sodium sulfate, the toluene phase is heated for 15 minutes to a stream of nitrogen and then cooled to room temperature. 2.5 ml of freshly distilled diethylamine was added to the toluene solution and stirred for 1 hour in a stream of nitrogen. After concentration under reduced pressure, an oil (1.0 g) is obtained, from which 1,1-Diethyl-3- (2-bromo-9,10-didehydro-6-methyl-8c-ergolinyl) is isolated on a thin layer by preparative chromatography. urea M.p. 204-208 ° C. Example5. 0.80 mg of 1,1-diethyl 3- (6-methyl-8-ergolinyl) -urea is stirred in 80 ml of dioxane with 0.80 g of N-bromosuccinimide for 3.5 hours at room temperature in the absence of light and in nitrogen atmosphere then filtered. The residue is washed with dioxane (2-50 ml). The combined filtrates are concentrated under reduced pressure to an oil, crystallized using 20 ml of ethyl acetate, the separated crystals are washed with ethyl acetate (2 5 ml) and dried. The crude product is first recrystallized from ethyl acetate / methanol (95: 5) using activated carbon and then precipitated from methanol with ether. 370 mg of 1,1-diethyl-3 - (- bromo-6-methyl8o (.-Ergolinyl) urea) are obtained in the form of a hydrobromic acid salt with a melting point of 226-228 ° C (with decomposition), (oL) to 62, 9 ° in pyridine (, 5). Approximately 1.0 g of 1,1-diethyl 3- (6-methyl-8 (/ 5-ergolinyl) -urea) dissolve 15 ml of tetrahydrofuran containing 10% hexamethylphospho triamide. Then add at room temperature 2.0 g of phenyltrimethylammonium perbromide are dripped in drops for 10 minutes and the reaction mixture is stirred for 6 hours at room temperature under a nitrogen atmosphere in the absence of air, then filtered. The residue (1.37 g) is washed 20 ml of tetrahydrofuran are poured in. The tetrahydrofuran filtrate is poured into 500 ml of ether, the crystalline precipitate is separated and chromatographed along with the precipitate in chloroform through neutral alumina. 650 mg of 1,1-diethyl-3- (2-bromo-methyl-methyl Bp-ergolinyl) urea, mp 194-195 C, (o (.) J, 71.2 ° C (in pyridine). To form hydrobromic acid salt 240 mg 1,1-diethyl 3- (2-bromo The -6-methyl-8/1-ergolinyl) urea is dissolved in 3 ml of acetone and transferred to 100 ml of ether in which 70 mg of hydrogen bromide gas is dissolved. The precipitate is filtered off, washed first with ether and then with 3 ml of acetone. 240 ml of hydrobromic acid salt are obtained, m.p. 212 ° C. EXAMPLE 7 676 mg of 3- (9,10-didehydro-6-methyl-8/1-ergolinyl) -1,1 diethyl urea (2 mol) is dissolved in 38 ml of anhydrous acetonitrile and, when cooled, to A solution of 0.6 ml of boron fluoride etherate in 10 gl of anhydrous methylene chloride is added to the atmosphere of inert gas at -5 °. A solution of 0.18 ml of freshly distilled sulphuryl chloride in 20 ml of anhydrous methylene chloride is added dropwise under the same conditions within 10 minutes. After 30 minutes, this solution is transferred to a cooled 5% aqueous ammonia solution, extracted with methylene chloride, the organic phase is dried over magnesium sulphate and evaporated. 420 ml of 3- (2-chloro 9,10-didehydro-6-methyl-80-ergolinyl 1,1-diethyl urea, (ct) p + 51 ° (chloroform) are graphically separated from the crude product of the hretlato graphically. Example. , 340 mg of 1,1-diethyl-3 (6-methylergolinyl) urea (1 mmol in 19 ml of anhydrous acetonitrile and 0.3 ml of boron fluoride ester in 5 ml of methylene chloride, dissolved in 0.09 m of freshly distilled sulfonyl chloride, dissolved in 10 ml of anhydrous methylene chloride. Processing and xp mapping performed analogs of Example 7. 270 mg of 3- (2-chloro-6-methyl-8-ergolinyl) -1,1-diethyl urea are obtained , () -60 (chloroform) Example 9: Analogously to Example 7, from 1 mmol of 1, l-diethyl-3- (9,10-didehydro-8-ergolinyl) -urea is obtained (yield 40%) 1,1-diethyl-3- (2-chloro-9, U-di-dehydro-Bob-ergopinyl) urea, (i) j) + 326 ° (chloroform). Similarly, from 2 d mol of the starting product of formula 1}, the corresponding 2-halo compounds listed in Table 1. Table 1,1-Diethyl-3- (2-chloro-8-1-ergolinyl) -urea71 + 48 1,1-Diethyl-3- (2-chloro-6-ethyl-8Y-ergolinyl) urea93 + 5 1,1-Diethyl-3- (2-chloro-6-ethyl-9, 10-didehydro8o (y-ergolinyl) urea 98 +196 1,1-Diethyl-3- (2-chloro 6-n-yropyl-8 ergolinyl) ) -urea90 + 13 1,1-Diethyl-3- (2- Lorb-n-propyl-9, 1C-didehydro-8 ° C-ergolinyl) urea92 1,1-Diethyl-3-G2-HLOR6- (2-propenyl) -8c6-Ergolinyl-urea 26-2 1/1-Diethyl-3- 2-chloro-6- (2-propenyl) -9,10Didehydro-YO-ergol nyl3-urea21 Example 10. 1 mmol of the starting product of the formula IT is dissolved in I with 150 ml of anhydrous dioxane, cooled in an ice bath, treated with 650 mg of pyrrolidnone hydrobperbromide ( 2 mol) and stirred at room temperature or with external ice cooling. The progress of the reaction is monitored by chromatography and, if necessary, a small amount of brominating agent is added. Then 50 ml of acetone and concentrated ammonia solution are added until alkaline. The methylene chloride is removed, the organic phase is dried over magnesium sulphate and chromatographed over silica gel. The compounds obtained are given in table. 2. T a l i c a 2 1,1-Diethyl-3- (2-bromo-cr-zrgolinil) -urea 89 1,1-Diethyl-3- (2-bromo9, 10-didehydro-8 ° C ergolinyl) - urea 79 1,1-Diethyl-3- (2-bromo-6-methyl-8Y-ergononyl) urea92 1,1-Diethyl-3- (2-bromo-6-ethyl-8 A-ergolinyl) urea 84 1,1-Diethyl-3 - (2-bromo-6-ETHIL-9, 10-didehydro-ergolinyl) -urea 73 1,1.-Diethyl-3- (2-bromo-6-n-propyl-8c-ergolinyl) urea 75 1,1-Diethyl-3- (2-Bromo-6-n-propyl-9, 10-didehydro-8oC-ergolinyl) urea 1,1-Diethyl-3-2-bromo-6- (2-propenyl) -8oi-3pginyl-urea 1,1-Diethyl-3 - 2-bromo-6- (2-propenyl) -9,10-dehydro-8o-ergolinyl-urea Example 11. 1 mmol of starting product were grown Op dissolved in 20 ml anhydrous dioxane was treated with 1.5 ml of N-ftodcyktsinimida at room temperature and stirred for 30 min. The reaction mixture is then poured into a saturated solution of bicarbonate, extracted with methylene chloride, and the organic layer is dried over magnesium sulfate. After evaporation of the solvent, the residue is chromatographed on silica gel. The compounds obtained are given in table. 3. Table 1,1-Diethyl-3- {2-iodo6-metsh1-8o1-ergolinyl) urea76 + 8 1,1-Diethyl-3- (2-iodo6-methyl-9, 10-didehydro-8o1-ergolinyl) - urea 23 + 168 Example 12, 0.5 mmol of 2-haloergoline derivative dissolved in 1 ml of methylene chloride, and a solution of 0.25 mcp of tartaric acid in 1 ml of methanol is added. Tartrate precipitates sometimes only after the addition of a small amount of diisopropyl ether. The resulting tartrates are given in table. 4. T a b l and d. A
    1,1-Diethyl-3 (2-chloro-6-methyl-8-C ergolinyl) urea tartrate
    1,1-Diethyl-3 (2-chloro-6-methyl-8/1-ergolinyl) urea tartrate
    In tab. 5 shows the test results of the proposed compounds (the effect of 2-halogen ergoline (L in MausSereen), the dose subcutaneously administered to at least 2-3 experimental animals.,
    "J; Table5 Continued table. 4 i Tartrate 1,1-diethyl-3 (2-chloro-6-methyl-9,10Didehydro-8o1-ergolinyl) -urea 50 +245 Tartrate 1,1-diethyl-3 (2-chloro-6-methyl-9, 10-dehydro-8-ergolinyl) urea45 +92 Tartrate 1,1-diethyl-3 2-iodine-6-methyl-8Y-ergolinyl) -urea 78 +34 Tartrate 1, i-diethyl-3 (2-iodine-6-methyl -9,10-dehydro-8o1-ergolinyl) urea71 + 124 Hydrotartrate-1,1-fatyl 3- (2-bplOM-6-n-propyl-8c erginyl) -urea 65 +18 Tartrate 1, l-diethyl-3 (2- Brpm-6-n-propyl-9, 1 0-dehydro-8o-ergolinyl) urea66 +165 1,1-Diethyl-3C2-HLOR-6- (2-propenyl) 8c tartrate-Ergolinyl-urea 65 +13 Hydrotagrate 1.1 -diethyl 3-2-chloro-b- (2-propenyl) 9,1O-didehydro-8-ergol inyl urea 49 + 182 Tartrate 1,1-diethyl-3 2-bromo-6- {2-propenyl8 (ergolinyl 3-urea 60 +12
    Continued table. five
    LlS - Lieurid
    TDHL - trans dihydrolizurid
    Thus, the proposed method allows to obtain new derivatives.
    ergolin alkaloids with valuable pharmacological properties.
    权利要求:
    Claims (1)
    [1]
    The method of obtaining derivatives of (2-haloergolinyl) -Ν 'Ν' -diethylurea of the General formula
    HH- <J0- ¥ (C 2 H 5 ) 2
    NK - or their salts, where R is hydrogen, methyl, ethyl, propyl or propenyl;
    X is a halogen atom;
    ~ ~ is a simple or double carbon-carbon bond, and the urea group can be in the C £ or ft position, characterized in that the ergoline derivative of the general formula where R has the indicated meanings and R * is the residue is N НСО-N (C 2 H 5) 2 or COOCH 3, the corresponding halogenated with a halogenating agent, if appropriate in the presence of a Lewis acid and if desired, an obtained 2-halo derivative is treated with hydrazine to give a hydrazide, followed by transfer action of nitrous acid, to the azide, which then thermally isomerize to the isocyanate and p dvergayut · reacted with diethyl amine, and the obtained target products were isolated in free form or in salt form.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1097199A3|1984-06-07|Process for preparing derivatives of |-n,n-diethylurea or their salts
    JP3421354B2|2003-06-30|Crystalline cefdiniramine salt
    KR20150028992A|2015-03-17|Manufacture of 2-|-4h-1,2,4-triazol-3-ylthio)acetic acid
    JPH0737460B2|1995-04-26|Pyranoindolizine derivative and method for producing the same
    HU191623B|1987-03-30|Process for production of ergoline-derivatives substituated by nitrogene-content in position 8 and medical preparatives containing thereof
    EP0126968B1|1988-12-21|Ergoline derivatives, processes for their preparation and pharmaceutical compositions containing same
    FI61188C|1982-06-10|FREQUENCY REQUIREMENTS FOR THE PREPARATION OF 8ALFA-CYANOMETHYLGOLIN-I-FOERENING WITH MEDICINAL PRODUCTS FOR PROLACTIC SECRETIONS
    SI21850A|2006-02-28|Salts of olanzapin and their transformation into free base of olanzapin
    EP0074921B1|1985-01-16|Process for the preparation of ergoline derivatives
    US5401748A|1995-03-28|2,14-disubstituted ergolines, their production and use in pharmaceutical compositions
    GB2116548A|1983-09-28|&gt;Ergolinylureas
    FI73968C|1987-12-10|Process for the preparation of phenylglycyl chloride hydrochlorides
    US4348392A|1982-09-07|8α-Substituted ergoline-I derivatives
    US4791115A|1988-12-13|2,6-dimethyl-8α-pivaloylamino-9,10-didehydro-ergoline
    US3428639A|1969-02-18|Preparation of ergot alkaloids
    FI71736C|1987-02-09|FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA ERGOLINDERIVAT OCH DERAS SYRAADDITIONSSALTER.
    Werber et al.1977|The synthesis and reactivity of some 2‐amino‐5‐bromo‐], 1, 3, 4‐thiadiazoles and the corresponding Δ2‐1, 3, 4‐thiadiazolines
    SU461500A3|1975-02-25|The method of obtaining heterocyclic compounds
    US4098790A|1978-07-04|Ergoline chlorination process
    US4035501A|1977-07-12|N-lysergyl-amino-pyridines
    SU922108A1|1982-04-23|Process for producing derivatives of 6-methyl-8-beta-hydrazinomethylergolin or their salts
    RU2002748C1|1993-11-15|Method of synthesis of 2,3,4,5-tetrahydro-5-methyl-2-[5- methyl-1h-imidazole- -4-yl) methyl]-1h-pyrido |-indole-1-one or ots salt
    JPH0662618B2|1994-08-17|Production of octahydropyrazolo [3,4-g quinolines
    KR790000947B1|1979-07-31|Process for preparing heterocyclic compounds
    KR800000047B1|1980-01-28|Process for preparing substituted 6-aryl-4h-s-triazolo-|-thieno-|-1,4-diazepines
    同族专利:
    公开号 | 公开日
    CS227048B2|1984-04-16|
    ES8307802A1|1983-08-16|
    YU307181A|1983-12-31|
    IE52849B1|1988-03-30|
    ES517919A0|1983-08-16|
    GR75159B|1984-07-13|
    DK13382A|1982-07-15|
    ES508735A0|1983-03-01|
    AT26716T|1987-05-15|
    CS227030B2|1984-04-16|
    DK161146C|1991-11-11|
    AU7929882A|1982-07-22|
    EP0056358B1|1987-04-22|
    DE3276114D1|1987-05-27|
    IE820066L|1982-07-14|
    HU186898B|1985-10-28|
    ES8304127A1|1983-03-01|
    EP0056358A1|1982-07-21|
    JPS57145875A|1982-09-09|
    AU547987B2|1985-11-14|
    DK161146B|1991-06-03|
    JPH0437079B2|1992-06-18|
    IL64745D0|1982-03-31|
    CA1175043A|1984-09-25|
    DE3101535A1|1982-08-12|
    DD202027A5|1983-08-24|
    US4853390A|1989-08-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CH573936A5|1971-08-05|1976-03-31|Spofa Vereinigte Pharma Werke|
    GB1517973A|1974-07-19|1978-07-19|Sandoz Ltd|6-methyl-8alpha-n,n-dimethylsulphamoylaminoergoline i|
    US4348392A|1974-07-19|1982-09-07|Sandoz Ltd.|8α-Substituted ergoline-I derivatives|
    CH615929A5|1975-06-02|1980-02-29|Sandoz Ag|Process for the preparation of novel ergoline compounds|
    DE2656344C2|1975-12-23|1990-11-08|Sandoz-Patent-Gmbh, 7850 Loerrach, De|
    DE2924102A1|1979-06-13|1980-12-18|Schering Ag|3-Ergolin-8-yl-1,1-di:ethyl-urea derivs. - useful as dopaminergic stimulants|
    EP0021206B1|1979-06-13|1983-06-22|Schering Aktiengesellschaft|-n', n'-diethyl urea derivatives, their preparation and pharmaceutical compositions containing them|
    DE3001752A1|1980-01-16|1981-07-30|Schering Ag Berlin Und Bergkamen, 1000 Berlin|METHOD FOR PRODUCING 8 SUBSTITUTED 6-METHYLERGOLINES|
    DE3101535A1|1981-01-14|1982-08-12|Schering Ag, 1000 Berlin Und 4619 Bergkamen|NEW -N'.N'-DIETHYL-UREA DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|
    DE3309493A1|1983-03-14|1984-09-20|Schering AG, 1000 Berlin und 4709 Bergkamen|NEW ERGOLIN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE AS A MEDICINAL PRODUCT|
    DE3340025C2|1983-11-03|1986-01-09|Schering AG, 1000 Berlin und 4709 Bergkamen|Process for the preparation of 2-bromo-8-ergolinyl compounds|DE3101535A1|1981-01-14|1982-08-12|Schering Ag, 1000 Berlin Und 4619 Bergkamen|NEW-N'.N'-DIETHYL-UREA DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|
    DE3216870A1|1982-05-03|1983-11-03|Schering AG, 1000 Berlin und 4709 Bergkamen|PHARMACEUTICAL PREPARATIONS WITH A CYTOSTATIC EFFECT|
    DE3309493A1|1983-03-14|1984-09-20|Schering AG, 1000 Berlin und 4709 Bergkamen|NEW ERGOLIN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE AS A MEDICINAL PRODUCT|
    PH21123A|1983-04-28|1987-07-27|Erba Farmitalia|Ergoline derivatives|
    DE3410218A1|1984-03-16|1985-09-19|Schering AG, Berlin und Bergkamen, 1000 Berlin|TERGURID AS AN ANTI-HYPERTENSIVE|
    DE3413659A1|1984-04-09|1985-10-17|Schering AG, 1000 Berlin und 4709 Bergkamen|Novel 2-substituted ergoline derivatives|
    DE3413657A1|1984-04-09|1985-10-17|Schering AG, 1000 Berlin und 4709 Bergkamen|Novel ergolines|
    CH666035A5|1984-12-24|1988-06-30|Sandoz Ag|8-ALPHA ACYLAMINOERGOLENE.|
    GB2173189B|1985-02-21|1988-04-27|Maruko Pharmaceutical Co|Ergoline derivatives and salts thereof and pharmaceutical compositions thereof|
    HU193317B|1985-06-12|1987-09-28|Richter Gedeon Vegyeszet|Process for producing 2-bromo-alpha-ergochristin|
    DE3522894A1|1985-06-24|1987-01-02|Schering Ag|USE OF TERGURID AS GERIATRIC|
    DE3533672A1|1985-09-19|1987-03-26|Schering Ag|NEW 12- AND 13-SUBSTITUTED ERGOL DERIVATIVES|
    DE3533675A1|1985-09-19|1987-03-26|Schering Ag|NEW 12- AND 13-BROMINE ERGOL DERIVATIVES|
    DE3535929A1|1985-10-04|1987-04-09|Schering Ag|1,2-DISUBSTITUTED ERGOL DERIVATIVES|
    DE3535930A1|1985-10-04|1987-04-09|Schering Ag|NEW 2-SUBSTITUTED ERGOL DERIVATIVES|
    DE3623438C2|1986-07-10|1998-04-09|Schering Ag|Ergolinyl urea derivatives labeled in the 2-position with radioactive iodine, process for their preparation and their use as diagnostics|
    US5242678A|1986-07-10|1993-09-07|Schering Aktiengesellschaft|BR-diagnostics for monoamine receptors|
    GB8824744D0|1988-10-21|1988-11-30|Erba Carlo Spa|Antiemesis ergoline derivatives|
    DE10043321B4|2000-08-24|2005-07-28|Neurobiotec Gmbh|Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and for lactation inhibition|
    GB0307377D0|2003-03-31|2003-05-07|Merad Pharmaceuticals Ltd|Ergoline derivatives|
    EP2067780A1|2007-12-07|2009-06-10|Axxonis Pharma AG|Ergoline derivatives as selective radical scavengers for neurons|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19813101535|DE3101535A1|1981-01-14|1981-01-14|NEW-N'.N'-DIETHYL-UREA DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|
    [返回顶部]